Risk Factors for Post-ESWL and Post-ERCP Pancreatitis

Completed

• Conditions: Risk Factors; Chronic Pancreatitis; ERCP; ESWL

• Registration Number: NCT04619511
• Lead Sponsor: Changhai Hospital

Brief Summary

The study aimed to identify risk factors for post-ERCP pancreatitis(PEP) after ESWL, and the relationship between the occurrence of post-ESWL pancreatitis and PEP.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-10-31
• Primary Completion: 2019-07-31
• Study Completion: 2019-07-31
• Status Verified: 2020-11
• Study First Submitted: 2020-11-03
• Study First Submitted QC: 2020-11-03
• Last Update Submitted: 2020-11-03
• Study First Posted: 2020-11-06
• Last Update Posted: 2020-11-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 714

Inclusion Criteria

• Patients diagnosed with chronic pancreatitis and treated with both ESWL and subsequent ERCP

Exclusion Criteria

• Patients with isolated pancreatic tail stone
• Patients with suspected or established malignancy
• Patients with pancreatic ascites
• Patients attending other interventional clinical trials
• Patients with non-correctable coagulation disorder
• Patients with pregnancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
post endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis	up to 1 months	The main outcome analyzed was the development of post-procedural pancreatitis, which was defined as clinical pancreatitis, meeting two of three the following criteria in accordance with the Revised Atlanta International consensus including pain consistent with AP; amylase or lipase more than 3 times the upper normal limit; characteristic findings on imaging.
post pancreatic extracorporeal shock wave lithotripsy (ESWL) pancreatitis	up to 1 months	The main outcome analyzed was the development of post-procedural pancreatitis, which was defined as clinical pancreatitis, meeting two of three the following criteria in accordance with the Revised Atlanta International consensus including pain consistent with AP; amylase or lipase more than 3 times the upper normal limit; characteristic findings on imaging.